These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 28888219

  • 21. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.
    Zhang F, Chen X, Wu T, Huang N, Li L, Yuan D, Xiang J, Wang N, Chen W, Zhang J.
    Clin Pharmacokinet; 2022 Jun; 61(6):881-893. PubMed ID: 35316848
    [Abstract] [Full Text] [Related]

  • 22. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
    Perzborn E, Heitmeier S, Buetehorn U, Laux V.
    J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
    [Abstract] [Full Text] [Related]

  • 23. Study on the Relationship between Rivaroxaban and Factor Xa Activity in Blood Based on HPLC-MS/MS.
    Liu H, Zhao Z, Wang Y, Liu L, Yang Y, An Z.
    Curr Drug Metab; 2021 Jul; 22(14):1132-1138. PubMed ID: 34825867
    [Abstract] [Full Text] [Related]

  • 24. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
    Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM.
    Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705
    [Abstract] [Full Text] [Related]

  • 25. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
    Schellings MW, Boonen K, Schmitz EM, Jonkers F, van den Heuvel DJ, Besselaar A, Hendriks JG, van de Kerkhof D.
    Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
    [Abstract] [Full Text] [Related]

  • 26. Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7).
    Suzuki S, Morishima Y, Takita A, Otsuka T, Yagi N, Arita T, Yamashita T.
    Heart Vessels; 2020 Mar; 35(3):409-416. PubMed ID: 31522245
    [Abstract] [Full Text] [Related]

  • 27. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
    Tobe A, Osanai H, Tanaka A, Sakaguchi T, Kambara T, Nakashima Y, Asano H, Ishii H, Ajioka M, Murohara T.
    Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
    [Abstract] [Full Text] [Related]

  • 28. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
    Königsbrügge O, Weigel G, Quehenberger P, Pabinger I, Ay C.
    Clin Exp Med; 2018 Aug; 18(3):325-336. PubMed ID: 29417256
    [Abstract] [Full Text] [Related]

  • 29. Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
    Derogis PB, Sanches LR, de Aranda VF, Colombini MP, Mangueira CL, Katz M, Faulhaber AC, Mendes CE, Ferreira CE, França CN, Guerra JC.
    PLoS One; 2017 Aug; 12(2):e0171272. PubMed ID: 28170419
    [Abstract] [Full Text] [Related]

  • 30. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban.
    Nakano Y, Kondo T, Osanai H, Murase Y, Nakashima Y, Asano H, Ajioka M, Sakai K, Inden Y, Murohara T.
    J Cardiol; 2015 Mar; 65(3):185-90. PubMed ID: 25192594
    [Abstract] [Full Text] [Related]

  • 31. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B, Würtinger P, Streif W, Sturm W, Fries D, Bachler M.
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [Abstract] [Full Text] [Related]

  • 32. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
    Liu Z, Xie Q, Zhang H, Mu G, Zhou S, Wang Z, Jiang J, Xiang Q, Cui Y.
    Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors.
    Ono R, Nishimura K, Takahashi H, Hori Y, Fukushima K, Kobayashi Y.
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):323-336. PubMed ID: 36326895
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
    Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, Mullier F.
    Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
    [Abstract] [Full Text] [Related]

  • 37. Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of 5 representative reagents in Japan (CVI ARO 1).
    Suzuki S, Yamashita T, Kasai H, Otsuka T, Sagara K.
    Thromb Res; 2017 Feb; 150():73-75. PubMed ID: 28043042
    [No Abstract] [Full Text] [Related]

  • 38. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
    Nakagawa J, Kinjo T, Iizuka M, Ueno K, Tomita H, Niioka T.
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
    Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Rönquist-Nii Y, Söderblom L, Östlund AY, Pohanka A, Antovic J, Malmström RE.
    Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.